Capillary Q2 FY27 consolidated revenue Rs 271.35 cr, PAT Rs 21.92 cr
Capillary Technologies India Ltd reported Q2 FY27 consolidated revenue from operations of Rs 271.35 cr and PAT of Rs 21.92 cr, up from Rs 179.33 cr and Rs 0.29 cr in Q2 FY26.
Key takeaways
- Revenue from operations was Rs 271.35 cr in Q2 FY27 vs Rs 179.33 cr in Q2 FY26.
- Total expenses rose to Rs 226.85 cr in Q2 FY27 from Rs 158.39 cr a year earlier.
- Adj. EBITDA increased to Rs 44.86 cr in Q2 FY27 from Rs 22.08 cr in Q2 FY26.
- PAT from continuing operations was Rs 21.92 cr vs Rs 0.29 cr in Q2 FY26.
- Depreciation and amortisation expenses were Rs 24.45 cr vs Rs 19.10 cr a year earlier.
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 271.35 cr | Rs 179.33 cr | +51.3% |
| PAT | Rs 21.92 cr | Rs 0.29 cr | +7448.3% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
-
Net margin was 8.08% of revenue, up 791 bps from 0.16%.
-
Revenue rose 51.3% while total expenses rose 43.2%.
-
Basis: Consolidated summary statement of profit and loss (Q2 FY27 vs Q2 FY26)
-
Revenue from operations: Rs 271.35 cr (Q2 FY27) vs Rs 179.33 cr (Q2 FY26)
-
Total expenses: Rs 226.85 cr (Q2 FY27) vs Rs 158.39 cr (Q2 FY26)
-
Other operating income: Rs 0.36 cr (Q2 FY27) vs Rs 1.15 cr (Q2 FY26)
-
Total operating expense: Rs 226.49 cr (Q2 FY27) vs Rs 157.24 cr (Q2 FY26)
-
Adj. EBITDA: Rs 44.86 cr (Q2 FY27) vs Rs 22.08 cr (Q2 FY26)
-
ESOP expenses: Rs 5.03 cr (Q2 FY27) vs Rs 2.29 cr (Q2 FY26)
-
Finance income, asset disposal profits, fair valuation and foreign exchange gains: Rs 5.70 cr (Q2 FY27) vs Rs 1.04 cr (Q2 FY26)
-
EBITDA: Rs 45.54 cr (Q2 FY27) vs Rs 20.83 cr (Q2 FY26)
-
Depreciation and amortisation expenses: Rs 24.45 cr (Q2 FY27) vs Rs 19.10 cr (Q2 FY26)
-
Finance costs: Rs 1.14 cr (Q2 FY27) vs Rs 1.77 cr (Q2 FY26)
-
Profit/(loss) before tax and exceptional items: Rs 19.94 cr (Q2 FY27) vs Rs (0.04) cr (Q2 FY26)
-
Tax expenses (net): Rs (1.97) cr (Q2 FY27) vs Rs (0.32) cr (Q2 FY26)
-
Exceptional loss / (income): Rs - (Q2 FY27) vs Rs - (Q2 FY26)
-
Profit/(loss) after tax from continuing operations: Rs 21.92 cr (Q2 FY27) vs Rs 0.29 cr (Q2 FY26)
According to the consolidated summary statement of profit and loss in the investor presentation, Capillary Technologies India Ltd’s revenue from operations for the quarter ended September 30, 2026 (Q2 FY27) rose to Rs 271.35 cr from Rs 179.33 cr in the corresponding quarter a year earlier (Q2 FY26). Total expenses increased to Rs 226.85 cr in Q2 FY27 from Rs 158.39 cr in Q2 FY26. Other operating income was Rs 0.36 cr in Q2 FY27 compared with Rs 1.15 cr in Q2 FY26, and total operating expense moved to Rs 226.49 cr from Rs 157.24 cr over the same period.
Adjusted EBITDA, as presented in the statement of profit and loss, improved to Rs 44.86 cr in Q2 FY27 from Rs 22.08 cr in Q2 FY26. ESOP expenses increased to Rs 5.03 cr from Rs 2.29 cr, while finance income, asset disposal profits, fair valuation and foreign exchange gains rose to Rs 5.70 cr from Rs 1.04 cr. EBITDA for the quarter stood at Rs 45.54 cr versus Rs 20.83 cr a year earlier. Depreciation and amortisation expenses were Rs 24.45 cr in Q2 FY27 compared with Rs 19.10 cr in Q2 FY26, and finance costs declined to Rs 1.14 cr from Rs 1.77 cr.
Profit/(loss) before tax and exceptional items turned to Rs 19.94 cr in Q2 FY27 from Rs (0.04) cr in Q2 FY26. Net tax expenses were Rs (1.97) cr in Q2 FY27 against Rs (0.32) cr in Q2 FY26. The statement shows no exceptional loss or income in either quarter. Profit/(loss) after tax from continuing operations increased to Rs 21.92 cr for Q2 FY27 from Rs 0.29 cr in the corresponding quarter of the previous year.
Track Capillary Technologies India Ltd
Cruxal reads every Capillary Technologies India Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
